New realities of phase I clinical trials in the era of immuno-oncology: the durvalumab experience
- 1 December 2019
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 30 (12), 2004-2007
- https://doi.org/10.1093/annonc/mdz401
Abstract
No abstract availableFunding Information
- AstraZeneca
This publication has 13 references indexed in Scilit:
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCThe New England Journal of Medicine, 2018
- Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with DurvalumabClinical Cancer Research, 2018
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyThe Lancet Oncology, 2018
- Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial CarcinomaClinical Pharmacology & Therapeutics, 2017
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusClinical Pharmacology & Therapeutics, 2017
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variabilityLaboratory Investigation, 2017
- Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung CancerClinical Cancer Research, 2017
- Exposure-efficacy and safety analysis of durvalumab in patients with urothelial carcinoma (UC) and other solid tumors.Journal of Clinical Oncology, 2017
- Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinomaDiagnostic Pathology, 2016
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009